Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

21.72
+0.77003.68%
Post-market: 21.71-0.0100-0.05%19:44 EDT
Volume:1.62M
Turnover:34.84M
Market Cap:2.18B
PE:-4.70
High:21.95
Open:21.00
Low:20.55
Close:20.95
Loading ...

Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
25 Feb

Beam Therapeutics Swings to Q4 Loss as Revenue Falls

MT Newswires Live
·
25 Feb

Earnings Flash (BEAM) Beam Therapeutics Posts Q4 License and Collaboration Revenue $30.1M, vs. FactSet Est of $17.2M

MT Newswires Live
·
25 Feb

Earnings Flash (BEAM) Beam Therapeutics Posts Q4 Net Loss $1.09 a Share, vs. FactSet Est of $1.23 Loss

MT Newswires Live
·
25 Feb

Beam Therapeutics Q4 2024 GAAP EPS $(1.09) Beats $(1.18) Estimate, Ended Fourth Quarter 2024 with $850.7M in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into 2027

Benzinga
·
25 Feb

Beam Therapeutics Inc: Cash Runway Expected to Support Operating Plans Into 2027

THOMSON REUTERS
·
25 Feb

Beam Therapeutics Q4 Operating Expenses USD 130.104 Million

THOMSON REUTERS
·
25 Feb

Beam Therapeutics Q4 EPS USD -1.09 VS. Ibes Estimate USD -1.2

THOMSON REUTERS
·
25 Feb

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

GlobeNewswire
·
25 Feb

AI Biotech Stocks Tumbled, with HIMS Plunging 17% and TEM Slumping 15%

Tiger Newspress
·
25 Feb

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

GlobeNewswire
·
24 Feb

Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025

Insider Monkey
·
24 Feb

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
21 Feb

CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?

Zacks
·
18 Feb

Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?

Zacks
·
10 Feb

Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Feb

Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Simply Wall St.
·
31 Jan

Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week

Simply Wall St.
·
31 Jan

Beam Therapeutics Raised to Overweight From Neutral by Cantor Fitzgerald

Dow Jones
·
29 Jan

Cantor Fitzgerald Upgrades Beam Therapeutics to Overweight From Neutral

MT Newswires Live
·
29 Jan